Aarti Drugs
Aarti Drugs Share Price Chart
Aarti Drugs last traded at ₹413.45 (2026-10-13). Over the past month the stock moved -5.2%, three months the stock moved +4.7%, year the stock moved -21.2%. Its closing range over 52 weeks is ₹330.60 – ₹518.15, with the latest close 20.2% below the high.
Closing prices up to 2026-10-13.
About Aarti Drugs
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]
Market Leadership:[1][2] The company is a leading global producer of 50+ API molecules across categories like antibiotics, antiprotozoal, anti-inflammatory, anti-diabetic, and anti-fungal. It is the largest manufacturer of Fluoroquinolones, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole worldwide, and among the top producers of Metformin globally.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Aarti Drugs reported sales of ₹703.00 crore (+19.0%) and net profit of ₹50.00 crore (-7.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 703.00 | 98.00 | 14.00 | 50.00 | 5.50 |
| Mar 2026 | 720.00 | 96.00 | 13.00 | 55.00 | 6.05 |
| Dec 2025 | 602.00 | 55.00 | 9.00 | 41.00 | 4.44 |
| Sep 2025 | 653.00 | 84.00 | 13.00 | 45.00 | 4.96 |
| Jun 2025 | 591.00 | 74.00 | 13.00 | 54.00 | 5.91 |
| Mar 2025 | 677.00 | 93.00 | 14.00 | 63.00 | 6.89 |
| Dec 2024 | 557.00 | 62.00 | 11.00 | 37.00 | 4.06 |
| Sep 2024 | 598.00 | 67.00 | 11.00 | 35.00 | 3.84 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -6.9% | -8.1% | +9.2% | +6.5% | +9.2% | +8.1% | +6.4% | +19.0% |
| Operating profit growth | -11.8% | -11.4% | +8.1% | +13.8% | +25.4% | -11.3% | +3.2% | +32.4% |
| Net profit growth | -12.5% | +0.0% | +34.0% | +63.6% | +28.6% | +10.8% | -12.7% | -7.4% |
| EPS growth | -10.9% | +1.8% | +33.8% | +63.3% | +29.2% | +9.4% | -12.2% | -6.9% |
| OPM % | 11.0% | 11.0% | 14.0% | 13.0% | 13.0% | 9.0% | 13.0% | 14.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Aarti Drugs reported sales of ₹2,565.00 crore (+7.5%) and net profit of ₹195.00 crore (+16.1%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2,565 | 309.00 | 12.00 | 195.00 | 21.36 |
| Mar 2025 | 2,387 | 287.00 | 12.00 | 168.00 | 18.29 |
| Mar 2024 | 2,529 | 321.00 | 13.00 | 172.00 | 18.65 |
| Mar 2023 | 2,716 | 309.00 | 11.00 | 166.00 | 17.96 |
| Mar 2022 | 2,489 | 333.00 | 13.00 | 205.00 | 22.14 |
| Mar 2021 | 2,155 | 440.00 | 20.00 | 280.00 | 30.09 |
| Mar 2020 | 1,806 | 266.00 | 15.00 | 141.00 | 15.17 |
| Mar 2019 | 1,561 | 211.00 | 14.00 | 90.00 | 9.52 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +25.5% | +15.7% | +19.3% | +15.5% | +9.1% | -6.9% | -5.6% | +7.5% |
| Operating profit growth | +4.5% | +26.1% | +65.4% | -24.3% | -7.2% | +3.9% | -10.6% | +7.7% |
| Net profit growth | +9.8% | +56.7% | +98.6% | -26.8% | -19.0% | +3.6% | -2.3% | +16.1% |
| EPS growth | +9.0% | +59.3% | +98.4% | -26.4% | -18.9% | +3.8% | -1.9% | +16.8% |
| OPM % | 14.0% | 15.0% | 20.0% | 13.0% | 11.0% | 13.0% | 12.0% | 12.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Aarti Drugs.
Get Free AI Stock Analysis FREE →Latest News
-
Aarti Drugs board meets Aug 27 to approve performance stock option plan - scanx.trade
-
Aarti Drugs consolidated net profit declines 6.94% in the June 2026 quarter - Business Standard
-
Aarti Drugs promoter group reduces stake by 1.67% via market sale - scanx.trade
-
Q4 Results Highlights Today: Profit surge for Uno Minda , NHPC, Styrenix, Aarti Drugs and LatentView Analytics; Vodafone Idea, Symphony, Celebrity Fashions, Balrampur Chini disappoint
-
Q4 Results Highlights Today 16th May, 2026: Profit surge for Uno Minda , NHPC, Styrenix, Aarti Drugs and LatentView Analytics; Vodafone Idea, Symphony, Celebrity Fashions, Balrampur Chini disappoint - BusinessLine
-
Q4 Results Today Live 16th May, 2026: Profit surge for Uno Minda , NHPC, Styrenix, Aarti Drugs and LatentView Analytics; Vodafone Idea, Symphony, Celebrity Fashions, Balrampur Chini disappoint - BusinessLine
-
Aarti Drugs. Share Price Today, Stock Price, Live BSE/NSE Prices and News for Aarti Drugs - NDTV Profit
-
Aarti Drugs consolidated net profit declines 12.20% in the March 2026 quarter - Business Standard
-
Aarti Drugs standalone net profit declines 26.87% in the March 2026 quarter - Business Standard
-
Q4 Results Highlights Today 16th May, 2026: Profit surge for Uno Minda , NHPC, Styrenix, Aarti Drugs and LatentView Analytics; Vodafone Idea, Symphony, Celebrity Fashions, Balrampur Chini disappoint - BusinessLine
Frequently Asked Questions
What is Aarti Drugs's current stock price?
Aarti Drugs shares were last quoted at ₹413.45 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Aarti Drugs?
Aarti Drugs has a price-to-earnings (P/E) ratio of 20.51 and a price-to-book (P/B) ratio of 2.45. The industry P/E is 53.33.
What is the 52-week high and low of Aarti Drugs?
The 52-week high of Aarti Drugs is ₹533.60 and the 52-week low is ₹318.60.
What is the market cap of Aarti Drugs?
The market capitalisation of Aarti Drugs is about ₹3,922.33 crore.
How did Aarti Drugs perform in its latest quarterly results?
In the latest quarter (Jun 2026), Aarti Drugs reported sales of ₹703.00 crore (+19.0%) and net profit of ₹50.00 crore (-7.4%), compared with the same quarter last year.
Is Aarti Drugs a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Aarti Drugs has a 3-year ROE of 13.00%, 3-year profit growth of 5.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Aarti Drugs?
Promoters hold about 54.43% of Aarti Drugs.
Which sector does Aarti Drugs belong to?
Aarti Drugs belongs to the Pharmaceuticals & Drugs sector.